Table 2.
Characteristics of the psychiatric genome-wide association studies utilised as outcomes.
| Outcome | Cases/Controls | SNP heritability | GWAS hits |
|---|---|---|---|
| Attention deficit/ hyperactivity disorder | 19,099/34,194 | 0.22 | 12 |
| Anorexia nervosa | 16,992/55,525 | 0.11 | 8 |
| Autism spectrum disorder | 18,381/27,969 | 0.12 | 5 |
| Bipolar disorder | 20,352/31,358 | 0.17 | 19 |
| Major depressive disorder | 59,851/113,154 | 0.08 (0.10)a | 44 (5)b |
| Obsessive compulsive disorder | 2688/7037 | 0.28 | 0 |
| Schizophrenia | 40,675/64,643 | 0.23 | 145 |
| Tourette’s syndrome | 4819/9488 | 0.21 | 1 |
SNP heritability reported on the liability scale assuming the following population prevalence: attention deficit hyperactive disorder = 5%, anorexia = 0.9%, autism = 1.2%, bipolar = 0.5%, major depressive disorder = 15%, schizophrenia = 0.7%, obsessive compulsive disorder = 2.5%, Tourette’s syndrome = 0.8%. GWAS hits denotes the number of independent, genome-wide significant variants reported by the original study.
aThe reported heritability estimate by the MDD publication is given, with the liability scale SNP-heritability for the publicly available subset in parentheses.
bThe MDD GWAS study reports 44 genome-wide significant SNPs, however, only a subset of this cohort has publicly available summary stats, and this subset has 5 genome-wide significant SNPs.